In another case–control study, the authors have investigated the use of the specific tau binding radioligand 18F-AV-1451 to differentiate disease in patients with PSP-RS, Alzheimer’s disease (AD) and mild cognitive impairment (MCI). This evidence concerns the gene MAPT and Alzheimer disease.